RBC Capital Maintains a Hold Rating on Gilead Sciences (GILD)

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best medical stocks to buy now. RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences, Inc. (NASDAQ:GILD) on September 29 and set a price target of $98.00.

Why Gilead Sciences (GILD) Deserves Attention in the Cheap Quarterly Dividend Stocks Category

Gilead Sciences, Inc. (NASDAQ:GILD) reported a 2% growth in its total revenues for fiscal Q2 2025 to $7.1 billion compared to the same period last year, with management attributing the growth to higher HIV, Livdelzi, and Trodelvy sales.

Diluted EPS for the quarter reached $1.56 compared to $1.29 in the prior year period, with the increase primarily driven by net unrealized gains on securities compared to net unrealized losses in 2024 and higher product sales.

Gilead Sciences, Inc. (NASDAQ:GILD) is a biotech company that advances medicines to prevent and treat serious diseases such as cancer, immunodeficiency virus (HIV), viral hepatitis, and COVID-19.

Its portfolio of drugs focuses on medical areas with unmet needs and includes AmBisome, Atripla, Biktarvy, Cayston, Complera, and others. Gilead Sciences, Inc. (NASDAQ:GILD) operates in over 35 countries.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.